October 2017: Dueling narratives on compulsory licensing emerge from the WTO TRIPS Council

The October 2017 meeting of the WTO TRIPS Council witnessed heated discussions on compulsory licensing within the context of IP and the Public Interest. As reported earlier by Knowledge Ecology International, on 31 May 2017, Brazil, China, Fiji, India, and… Continue Reading

KEI asks FTC to block Celgene Acquisition of Juno​ Therapeutics, over BCMA-targeted CAR T treatment for Multiple Myeloma

On February 14, 2018, KEI meet with the FTC to express our opposition to Celgene’s proposed acquisition of Juno Therapeutics. Celgene-Juno-KEI-FTC16Feb2018 The Celgene acquisition of Juno Therapeutics would give Celgene control over competing candidates for the treatment of multiple myeloma… Continue Reading

NIH Declines Request for the Budget for Clinical Trials Involving CAR T technology to be licensed to Kite/Gilead

On February 14, the NIH was asked what the budget was for the Phase 1 clinical trial of the anti-CD30 CAR T technology that is the subject of a proposed exclusive patent license to Kite/Gilead. The clinicaltrials.gov identifier for the… Continue Reading

PhRMA and BIO request EU be added to USTR Watch List over review of incentives

PhRMA and BIO have both requested that the US Trade Representative place the European Union on its watch list in the 2018 Special 301 Report. The Special 301 Report is a yearly review by the US Trade Representative of the… Continue Reading

PhRMA’s 2018 Special 301 Submission targets Australia, Canada, S. Korea, Japan & others over pricing, reimbursement policies

In its 2018 Special 301 submission, PhRMA targets a number of countries for pricing and reimbursement policies deemed hostile to the pharmaceutical industry. Among these, PhRMA strategically lobbies for the strongest classifications for Canada and Korea — countries dealing with… Continue Reading

EB142: KEI statement on WHO’s decision on the Global strategy and plan of action on public health, innovation and intellectual property

After lengthy negotiations, on Friday, 26 January 2018 the World Health Organization’s Executive Board approved a decision to reinvigorate the Organization’s work program on innovation and access to medicines. Here are two quotes from KEI on the decision: James Love,… Continue Reading

EB142: KEI statement on Preparation for the third High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases

The World Health Organization’s (WHO) Executive Board is expected to discuss agenda item 3.8 on Preparation for the third High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases, to be held in 2018 the either… Continue Reading